Takeda Pharmaceutical (TAK) Operating Expenses (2017 - 2026)

Takeda Pharmaceutical's Operating Expenses history runs 10 years deep, the most recent figure standing at $12.6 billion for Q1 2026.

• On a quarterly basis, Operating Expenses rose 810.97% year-over-year to $12.6 billion in Q1 2026; TTM through Mar 2026 was $3.3 billion, a 130.52% increase from a year earlier, with the FY2026 full-year figure at $4.7 billion, up 362.5% from the prior year.
• Operating Expenses advanced to $12.6 billion in Q1 2026 per TAK's latest filing, from -$1.9 billion in the prior quarter.
• Across five years, Operating Expenses topped out at $12.6 billion in Q1 2026 and bottomed at -$5.5 billion in Q3 2025.
• The 5-year median for Operating Expenses is -$1.9 billion (2025), against an average of -$1.9 billion.
• Across the five-year window, Operating Expenses plunged 123.06% in 2022 and soared 810.97% in 2026, its largest moves.
• Year by year, Operating Expenses stood at -$1.8 billion in 2022, then slipped by 6.98% to -$1.9 billion in 2023, then slipped by 0.88% to -$1.9 billion in 2024, then increased by 1.21% to -$1.9 billion in 2025, then soared by 754.4% to $12.6 billion in 2026.
• Per Business Quant, the three latest TAK Operating Expenses figures stand at $12.6 billion (Q1 2026), -$1.9 billion (Q4 2025), and -$5.5 billion (Q3 2025).